Indications
Verigat Tablet is used for:
Heart Failure Risk Reduction
Adult Dose
Heart Failure Risk Reduction
Indicated to reduce risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction <45%
Initial: 2.5 mg PO once daily
Maintenance: Double dose every 2 weeks as tolerated to target dose of 10 mg PO once daily
Hepatic impairment
Mild or moderate (Child-Pugh A or B): No dosage adjustment necessary
Severe (Child-Pugh C): Not studied
Child Dose
Renal Dose
Renal impairment
eGFR >15 mL/min/1.73m2 and not on dialysis: No dosage adjustment necessary
eGFR <15 mL/min/1.73m2 or on dialysis: Not studied
Administration
Should be taken with food
Contra Indications
Coadministration with other soluble guanylate cyclase (sGC) stimulators
May cause fetal harm when administered to pregnant females and its use is contraindicated
Precautions
May cause fetal harm; do not administer to pregnant females
Exclude pregnancy before starting treatment
To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for 1 month after stopping treatment
Pregnancy-Lactation
Pregnancy
Contraindicated; based on data from animal reproduction studies, may cause fetal harm when administered to pregnant females
There are no available data regarding use in pregnant females
Verify pregnancy status in females of reproductive potential before initiating
Animal studies
Administration to pregnant rabbits during organogenesis at ?4 times the human exposure (total AUC) with the maximum recommended human dose (MRHD) of 10 mg resulted in malformations of the heart and major vessels, as well as increased number of abortions and resorptions
In a prenatal/postnatal toxicity study, oral administration to rats during gestation through lactation caused maternal toxicity, resulting in decreased pup body weight gain (>10 times the MRHD) and increased pup mortality (24 times the MRHD) during the preweaning period
Contraception
Advise females of reproductive potential to use effective contraception during treatment and for 1 month after final dose
Lactation
Data are not available on the presence of vericiguat in human milk, effects on breastfed infants, or effects on milk production
Vericiguat is present in the milk of lactating rats and it is likely that vericiguat or its metabolites are present in human milk
Owing to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment
Interactions
Coadministration with other sGC stimulators is contraindicated
Coadministration with PDE-5 inhibitors not recommended owing to potential for hypotension
Side Effects
Side effects of Vericiguat :
>10%
Hypotension (16%); placebo (15%)
1-10%
Anemia (10%); placebo (7%)
Mode of Action
Stimulates soluble guanylate-cyclase (sGC), the intracellular receptor for endogenous nitric oxide (NO), which catalyzes cyclic guanosine monophosphate (cGMP) production; cGMP plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling
Heart failure is associated with impaired NO synthesis and decreased sGC activity, which may contribute to myocardial and vascular dysfunction
By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation
Note
Verigat 2.5 mg Tablet generic name is Vericiguat. Verigat 2.5 mg Tablet is manufactured by Acme Laboratories Ltd.Verigat is availble in all over Bangladesh.
Mes BD drug index information on Verigat Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.